List of Excipients in Branded Drug ERYTHROMYCIN

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Mylan Pharmaceuticals Inc	ERYTHROMYCIN	erythromycin	0378-8212	ALCOHOL
Mylan Pharmaceuticals Inc	ERYTHROMYCIN	erythromycin	0378-8212	HYDROXYPROPYL CELLULOSE
Mayne Pharma Inc	ERYTHROMYCIN	erythromycin	68308-250	FD&C YELLOW NO. 6

Generic Drugs Containing ERYTHROMYCIN

Company	Ingredient	NDC	Excipient
Teva Pharmaceuticals USA Inc	erythromycin	0093-5571	CROSCARMELLOSE SODIUM
Teva Pharmaceuticals USA Inc	erythromycin	0093-5571	CROSPOVIDONE
Teva Pharmaceuticals USA Inc	erythromycin	0093-5571	FD&C RED NO. 40

What are the Most Frequently-Used Excipients in ERYTHROMYCIN?

# Of NDCs	Excipient
16	ALCOHOL
10	ALUMINUM OXIDE
4	ANHYDROUS CITRIC ACID

Erythromycin Excipient Strategy and Commercial Opportunities

Last updated: September 24, 2026

Erythromycin is a mature macrolide with limited composition-of-matter protection and substantial generic competition. Commercial value now depends on formulation performance, patient adherence, pediatric usability, local delivery, stability, and manufacturing cost. The strongest opportunities are taste-masked oral liquids, gastroprotected oral products, ophthalmic and topical delivery systems, and differentiated combination products rather than conventional immediate-release tablets.

What is the current pharmaceutical and regulatory status of erythromycin?

Erythromycin is an FDA-approved antibacterial active available in multiple salts and dosage forms. Products include oral tablets, capsules, granules for suspension, delayed-release tablets, ophthalmic ointments, topical gels and solutions, and injectable formulations.

The principal commercial forms are:

Form	Primary formulation purpose	Representative use
Erythromycin base	Active macrolide, generally acid-sensitive	Oral solid dosage forms, topical products
Erythromycin ethylsuccinate	Improved oral acceptability and suspension utility	Pediatric oral suspension and tablets
Erythromycin stearate	Oral salt with improved handling and release characteristics	Tablets and capsules
Erythromycin estolate	Oral ester prodrug form	Historical oral products; reduced commercial importance
Erythromycin lactobionate	Water-soluble injectable salt	Intravenous administration
Erythromycin gluceptate	Injectable salt	Historical parenteral products
Erythromycin ophthalmic base	Local ophthalmic treatment	Ointments and ophthalmic preparations

Erythromycin is regulated as a small-molecule drug. It has no biosimilar pathway because biosimilars apply to biologic products, not chemically synthesized or fermented small-molecule antibiotics. Generic competition proceeds primarily through abbreviated new drug applications, or ANDAs.

FDA labeling identifies erythromycin as a macrolide antibacterial and includes warnings involving hepatotoxicity, QT prolongation, drug interactions, infantile hypertrophic pyloric stenosis, and antimicrobial resistance [1-4].

What excipient problems create commercial opportunities for erythromycin?

The central formulation issue is erythromycin’s acid instability. Gastric acid can degrade erythromycin and reduce effective exposure. Formulators therefore use salts, enteric coatings, delayed-release systems, protective matrices, and prodrug forms to improve gastrointestinal performance.

The main excipient and delivery challenges are:

1. Acid protection.
2. Bitter taste and pediatric acceptability.
3. Suspension stability.
4. Moisture sensitivity.
5. Dose uniformity in low-dose liquid products.
6. Ointment spreadability and patient comfort.
7. Chemical compatibility with preservatives, buffers, surfactants, and packaging.
8. Control of polymorphism and solid-state behavior.
9. Palatability without excessive sugar or alcohol.
10. Reproducible dissolution after coating or granulation.

These constraints create room for formulation differentiation even though the active ingredient is generic.

Acid protection and delayed release

Erythromycin base is vulnerable to degradation in acidic conditions. Commercial strategies include:

• Enteric polymers such as methacrylic acid copolymers.
• Cellulose acetate phthalate.
• Hypromellose phthalate.
• Polyvinyl acetate phthalate.
• Alkaline microenvironments created with carbonate or bicarbonate excipients.
• Multiparticulate pellets with delayed-release coatings.
• Tablets combining protective cores with pH-dependent outer layers.

A robust formulation must avoid premature release in the stomach while releasing the active ingredient consistently in the upper intestine. Coating weight gain, polymer grade, plasticizer concentration, and dissolution test design materially affect product performance.

Which excipients are most relevant to erythromycin product development?

Oral tablets and capsules

Common excipient classes include:

• Microcrystalline cellulose for compression and capsule fill.
• Lactose, mannitol, or dibasic calcium phosphate as diluents.
• Crospovidone, croscarmellose sodium, or sodium starch glycolate as disintegrants.
• Povidone or hypromellose as binders.
• Colloidal silicon dioxide as a glidant.
• Magnesium stearate or sodium stearyl fumarate as lubricants.
• Hypromellose or polyvinyl alcohol as film-coating polymers.
• Methacrylic acid copolymers for enteric protection.
• Triethyl citrate or polyethylene glycol as plasticizers.

Formulators should control lubricant concentration and blending time because excessive hydrophobic lubrication can delay dissolution. This issue becomes more important when the product already relies on rapid intestinal release after an enteric trigger.

Pediatric oral suspensions

Pediatric suspension products have the clearest excipient-led differentiation potential. Erythromycin ethylsuccinate is widely used because it supports oral liquid development and is generally more acceptable than unmodified erythromycin base.

Relevant excipient systems include:

• Sucrose, sorbitol, xylitol, or maltitol for sweetness and bulk.
• Sucralose, saccharin sodium, or acesulfame potassium for high-intensity sweetness.
• Xanthan gum, sodium carboxymethylcellulose, or microcrystalline cellulose and carboxymethylcellulose for suspension rheology.
• Citrate or phosphate buffers for pH control.
• Polysorbates or other wetting agents.
• Sodium benzoate or potassium sorbate where compatible with pH.
• Fruit or tutti-frutti flavors.
• Chelating agents such as disodium edetate when justified by stability data.

Commercial formulations should address sugar reduction, alcohol avoidance, preservative minimization, and easy redispersion. A product that remains dose-uniform after storage and requires limited shaking can compete in pediatric and outpatient settings even without a new active ingredient.

Ophthalmic ointments and gels

Ophthalmic erythromycin products generally use a sterile petrolatum and mineral oil base. Commercial opportunities exist in:

• Lower-blur ointment bases.
• More uniform drug dispersion.
• Ophthalmic gels with improved residence time.
• Preservative-free single-dose packaging.
• Unit-dose tubes that reduce contamination risk.
• Formulations designed for neonatal use.

Ophthalmic products require tight control of sterility, particle size, assay uniformity, container-closure integrity, and ocular tolerability. A formulation that reduces transient visual blurring may have a practical advantage over conventional petrolatum ointment.

Topical products

Topical erythromycin has historically been used in acne products, often with alcohol, propylene glycol, carbomer, or hydroalcoholic vehicles. The commercial position of topical erythromycin is weakened by antimicrobial-resistance concerns and competition from benzoyl peroxide, clindamycin combinations, retinoids, and newer acne therapies.

Potential formulation angles include:

• Reduced-irritation gels.
• Non-stinging aqueous systems.
• Combination products with benzoyl peroxide or anti-inflammatory agents.
• Film-forming systems that improve contact time.
• Lower-residue lotions and foams.
• Preservative-free or low-preservative packaging.

Any topical strategy must address resistance stewardship and avoid positioning erythromycin as a routine long-term monotherapy.

What formulations are protected by erythromycin patents?

The foundational erythromycin composition-of-matter protection expired decades ago. U.S. Patent No. 2,653,899, associated with erythromycin, was issued in 1953 and does not create a current U.S. market barrier [5].

Later patent activity focused on:

• Erythromycin salts and esters.
• Enteric-coated tablets.
• Delayed-release systems.
• Granules for oral suspension.
• Stabilized liquid formulations.
• Topical and ophthalmic vehicles.
• Combination products.
• Manufacturing and purification processes.

Most early erythromycin formulation patents have also expired. Current patent risk is more likely to arise from narrow formulation claims, device claims, packaging, or method-of-use claims than from the active ingredient itself. A commercial diligence review should separate:

Patent category	Present relevance
Original erythromycin compound patents	None in ordinary U.S. generic competition
Salt and ester patents	Usually expired; may affect historical product architecture
Enteric coating patents	Potentially relevant only if newer claim scope remains unexpired
Suspension and taste-masking patents	Possible relevance for differentiated pediatric products
Ophthalmic delivery patents	Potentially relevant for newer gel or preservative-free systems
Manufacturing patents	Relevant where process specificity creates non-obvious quality advantages
Method-of-use patents	Possible relevance in narrowly claimed indications
Packaging and device patents	Relevant for unit-dose and reconstitution systems

Patent freedom-to-operate depends on the exact formulation, jurisdiction, filing date, patent-term adjustment, terminal disclaimer, and claim scope. The commercial baseline remains open because erythromycin is a long-established generic active.

What is the Orange Book status of erythromycin?

The FDA Orange Book lists approved drug products and, where applicable, patent and exclusivity information. Erythromycin products have historically appeared in multiple dosage forms and salt forms, including tablets, capsules, suspensions, ophthalmic preparations, and injectable products [6].

For most mature erythromycin products:

• New chemical entity exclusivity has expired.
• Pediatric exclusivity associated with older products has expired.
• Generic substitution is established in many dosage forms.
• Orange Book patent listings, where present, are product-specific rather than representative of the entire erythromycin market.
• A listed patent for one salt, dosage form, or indication does not automatically block another erythromycin product.

A sponsor pursuing an ANDA must evaluate the reference listed drug, listed patents, certification pathway, bioequivalence method, inactive-ingredient differences, and any product-specific labeling requirements. For a new dosage form or clinically differentiated product, a 505(b)(2) application may be more suitable than an ANDA.

When does erythromycin lose exclusivity, and what generic entry risks exist?

Erythromycin’s core exclusivity has already expired. Generic entry risk is therefore high for standard tablets, capsules, oral suspensions, topical solutions, and ophthalmic ointments.

The principal generic launch scenarios are:

Product strategy	Generic entry risk	Commercial implication
Conventional immediate-release tablet	Very high	Price competition dominates
Standard oral suspension	High	Taste, stability, and supply reliability are differentiators
Enteric-coated tablet	High to moderate	Dissolution and coating performance may create execution barriers
Preservative-free ophthalmic unit dose	Moderate	Sterile manufacturing and packaging raise barriers
Novel ophthalmic gel	Moderate	Clinical bridging and formulation patents may provide differentiation
Long-acting local delivery	Lower initially	Development cost and regulatory complexity are high
Combination topical product	Moderate	Clinical positioning and resistance concerns affect demand
Injectable lactobionate product	Moderate	Sterile manufacturing and hospital supply reliability matter

Paragraph IV challenges are relevant only where a current Orange Book-listed patent covers the selected reference product. Because erythromycin has a mature generic market, the greater practical risk is often not patent litigation but rapid price erosion after approval.

Which companies are challenging erythromycin products?

Generic competition has historically included major manufacturers such as Teva, Hikma, Zydus, Sandoz, Amneal, Rising Pharmaceuticals, and other regional suppliers, depending on the dosage form and market. Brand and authorized-generic participation has varied over time.

The competitive field is fragmented by product type:

• Large generic companies compete in tablets, capsules, and oral liquids.
• Specialty sterile manufacturers compete in injectable products.
• Ophthalmic specialists compete in ointments and preservative-free systems.
• Contract manufacturers supply private-label and institutional products.
• Compounding pharmacies may serve limited formulations but do not replace FDA-approved commercial products.

The most defensible commercial position is usually a reliable supply niche, a difficult-to-manufacture dosage form, or a clinically meaningful administration advantage.

How strong is the erythromycin patent estate?

The active-ingredient patent estate is weak because the foundational patents are expired. The formulation estate is fragmented and generally narrow.

A practical strength assessment is:

Estate component	Strength
Composition of matter	Exhausted
Conventional oral dosage forms	Weak
Salt and ester chemistry	Historically important, generally expired
Enteric-coated delivery	Moderate only where newer claims remain active
Pediatric taste masking	Potentially moderate for narrowly claimed systems
Ophthalmic gels and unit-dose delivery	Moderate, dependent on claim and filing date
Manufacturing and purification	Moderate if process produces measurable quality advantages
Method of use	Limited and indication-specific
Regulatory exclusivity	Low for established products

Formulation patents should be drafted around measurable performance: acid-stage protection, intestinal release, suspension redispersibility, microbial stability, taste-panel outcomes, reduced degradation products, or improved ocular residence time. Broad claims covering ordinary excipient combinations face substantial validity and obviousness risk.

What licensing deals and partnerships could support erythromycin commercialization?

Licensing value is more likely to arise from technology than from the erythromycin molecule. Relevant partnership targets include:

• Taste-masking platforms.
• Multiparticulate coating technologies.
• Sterile ophthalmic filling and unit-dose packaging.
• Pediatric liquid manufacturing.
• Continuous granulation and coating platforms.
• Preservative-free delivery systems.
• Hospital injectable supply networks.
• Regional distribution agreements in markets with limited macrolide availability.

A licensor should seek claims and know-how covering process controls, coating parameters, stability data, analytical methods, and packaging compatibility. A license limited to a basic excipient mixture is less defensible because equivalent systems may be developed around it.

What FDA regulatory pathway applies to new erythromycin products?

The pathway depends on the product’s relationship to an approved reference:

ANDA

An ANDA is appropriate for a generic product that matches the reference in active ingredient, dosage form, strength, route, conditions of use, and other required characteristics. Bioequivalence and inactive-ingredient acceptability are central.

505(b)(2)

A 505(b)(2) application may be appropriate for:

• A new salt or ester.
• A new ophthalmic delivery system.
• A new route or dosage form.
• A modified-release product.
• A product relying partly on published literature or prior FDA findings.

A 505(b)(2) product may obtain three years of marketing exclusivity for qualifying new clinical investigations, but this does not recreate composition-of-matter exclusivity.

Drug Master File and contract manufacturing strategy

Excipient suppliers can support sponsors through Type IV Drug Master Files, while manufacturers may use Type II DMFs for active-substance processes. Commercial value increases when the supplier controls a validated, scalable process rather than merely selling a commodity excipient.

How does erythromycin compare with azithromycin and clarithromycin?

Attribute	Erythromycin	Clarithromycin	Azithromycin
Market age	Oldest of the three	Mature	Mature
Acid stability	Poor for base	Improved relative to erythromycin	Improved
Dosing convenience	Generally less favorable	Twice daily in many uses	Often once daily
Pediatric formulation opportunity	High	Moderate	High
Taste-masking need	High	High	High
Generic competition	Very high	Very high	Very high
Formulation differentiation	Suspension, ophthalmic, enteric, topical	Modified release and suspension	Suspension, extended exposure, pediatric delivery
Resistance and stewardship pressure	High	High	High

Erythromycin can compete where low cost, established clinical familiarity, neonatal or ophthalmic use, or specific formulation requirements matter. It is less competitive where simplified dosing and acid stability are the dominant purchasing criteria.

What revenue exposure and commercial upside exist?

Revenue exposure is highest for companies selling standard oral erythromycin into retail generic channels. These products face:

• Multiple approved suppliers.
• Pharmacy substitution.
• Tender-driven pricing.
• Stocking and shortage risks.
• Low switching costs.
• Limited differentiation from conventional competitors.

Commercial upside is greater in products with operational barriers:

1. Preservative-free ophthalmic presentations.
2. Stable, palatable pediatric suspensions.
3. Reconstitution systems with long in-use stability.
4. Enteric-coated multiparticulates.
5. Hospital injectables with dependable supply.
6. Low-irritation topical combinations.
7. Regional products addressing shortages or limited supplier coverage.

The most attractive strategy is a portfolio rather than a single tablet product. A sponsor could combine an approved oral suspension, an ophthalmic product, and a differentiated sterile or preservative-free presentation using shared erythromycin sourcing and analytical infrastructure.

Key Takeaways

• Erythromycin’s core patents and regulatory exclusivities are expired.
• Conventional tablets and capsules have weak differentiation and high generic entry risk.
• Excipient strategy is most valuable in acid protection, taste masking, suspension stability, ophthalmic tolerability, and sterile packaging.
• Pediatric oral liquids and preservative-free ophthalmic products offer the strongest formulation-led opportunities.
• A 505(b)(2) pathway may support genuinely differentiated salts, delivery systems, or dosage forms.
• Patent value is more likely to come from narrow formulation, process, packaging, and delivery claims than from the erythromycin molecule.
• Commercial success depends on manufacturing reliability, palatability, supply continuity, and clinically relevant administration advantages.

FAQs About Erythromycin Excipient and Formulation Opportunities

Can erythromycin be reformulated as a sugar-free pediatric suspension?

Yes. Sorbitol, xylitol, maltitol, and high-intensity sweeteners can replace sucrose, subject to palatability, osmolarity, preservative compatibility, gastrointestinal tolerance, and stability requirements.

Which excipients improve erythromycin taste?

Sweeteners, flavors, ion-exchange resins, polymeric coatings, lipid barriers, and multiparticulate encapsulation can reduce bitterness. The best approach depends on the salt, dose, release profile, and required reconstitution stability.

Does erythromycin require an enteric coating?

Not every erythromycin product requires one. Acid-sensitive erythromycin base commonly benefits from enteric protection or another gastroprotective design, while certain salts and ester forms may use different stabilization strategies.

Is erythromycin a good candidate for a 505(b)(2) product?

It can be, particularly for novel ophthalmic delivery, modified release, new salts, preservative-free systems, or other products that cannot qualify as straightforward ANDAs.

Are erythromycin excipient patents commercially defensible?

They can be defensible when claims are tied to reproducible technical results such as acid-stage protection, improved dissolution, suspension redispersibility, reduced degradation, enhanced ocular residence, or superior patient acceptability.

References

1. U.S. Food and Drug Administration. (2023). Erythromycin ethylsuccinate oral suspension prescribing information. FDA/DailyMed.

2. U.S. Food and Drug Administration. (2023). Erythromycin delayed-release tablets prescribing information. FDA/DailyMed.

3. U.S. Food and Drug Administration. (2023). Erythromycin ophthalmic ointment prescribing information. FDA/DailyMed.

4. U.S. Food and Drug Administration. (2022). Erythromycin lactobionate injection prescribing information. FDA/DailyMed.

5. McGuire, J. M., et al. (1953). Erythromycin (U.S. Patent No. 2,653,899). U.S. Patent and Trademark Office.

6. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. FDA, Center for Drug Evaluation and Research.